CLIPS BnC
- Biotech or pharma, therapeutic R&D
- CMO, CRO
CLIPS BnC is a new drug development company established in South Korea in 2015. It started as a clinical Contract Research Organization (CRO) and is now developing biopharmaceuticals. Its core pipeline includes two key candidates: LSCD101, a limbal stem cell therapy for treating limbal stem cell deficiency (LSCD), an ophthalmic disease, and an MRSA vaccine aimed at preventing Staphylococcus aureus infections. LSCD101 is currently in Phase 2 clinical trials in Korea and has been designated as an orphan drug. The MRSA vaccine has demonstrated protective efficacy against the bacteria in non-clinical efficacy studies using rabbits and mice. The clinical CRO division generates annual revenue of over 10 billion KRW (approximately 10 million USD).
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}